Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With SAVA and ANAVEX reporting positive p2/p2/a/b data, the FDA won’t feel pressured to approve a negative drug from BIIB
Market on its way to being “woke”?
Out with the Amaloid in with the new
1/2 way there......
Yes, that is what I was referring to when I mentioned who was ahead of the game. Who would bring their drug to market first. One is a one trick pony, while the other has multiple shots on goal plus a free penalty kick for RETT.
BostonSportsNut is now TampaSportsNut. Hahaha. 1 more ring ftw
I meant between Anavex and that “other” company. Who has more years of data? Who can get to market first?
The things we should of/could of did when the sp was < $3.
401k locked and loaded
IRA 75% there
AS FAR AS RISK IM WILLING TO TAKE TO SEE THIS BABY BIO THROUGH TO THE END.
The spiel is getting old. Anavex can slowly climb to $16 and the same nonsense will be spewed.
And who’s ahead in the game.....?
Best quote I’ve read in a while, said by none other than the billionaire investor himself:
Chamath Palihapitiya
"Let's look at Tesla. Who was right on Tesla? I'll tell you who was right: every single retail investor. I was right. Elon Musk was right," Palihapitiya said. "Let me tell you who was wrong: every single hedge fund. Name after name, when it comes to innovation, when it comes to growth, when it comes to people trying to do fundamentally useful things in the world, if it doesn't fit into the mold that Wall Street wants, they try to organize against it."
Soon to one day hopefully hold true for Anavex stock as well.
She also just said she is taking metformin to help protect from cancer. That’s pumping as well?
Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum https://seekingalpha.com/article/4397480-anavex-life-sciences-corp-2021-clinical-milestones-support-bullish-momentum
“Now that we have to use cash as of today”
I think that sentence should read “now that we have two years cash as of today”
The accent fooled the dictation machine.
HA
As of the latest practicable date, 66,962,957 issued and outstanding as of Dec 28,2020
It states that as of Sept 30 2020, the outstanding shares are 58,194,894?
https://www.anavex.com/anavex-life-sciences-reports-fiscal-2020-year-end-financial-results-and-clinical-program-updates/
Bottom in Investors & Media:
My guess is Autism.
Just look at last week and how the Dr. will talk about Fragile X in less than 2 weeks. She also mentioned Autism as well so.....
Speaking of Dr. Hagerman,
Looks like she has another lecture about Fragile X and targeted treatments for FXS and ASD.
Mentioned: A-273
https://health.ucdavis.edu/mindinstitute/videos/images/dls/hagerman-2021-dls.pdf
Wow, the earlier the medication is taken, the better brain you’ll build
It’s over zoom and is being recorded.
This medication can be a “boon”
Sound coming through perfect here.
How many times have I heard that throughout the years......
Just be patient and watch the game.
Queue the Armageddon quote “ ITS NOT A MATTER OF IF........BUT WHEN “
Shareholders would approve a measly $1B-$5B?
You say:
“Therefore, the only logical conclusion I can draw is that Biogen and big pharmas in CNS generally don’t think much of Anavex.”
I say:
“The only reason we haven’t been bought out yet is because we are not for sale.”
It’s much like a broken car. The owner would willingly sell/trade to a dealership if it is in the best interest of himself.
We don’t have a broken car. We have a car so futuristic, the world isn’t yet ready to believe what they see.
They soon will though and everyone will want one.
That’s one way to think of it.
Another is wash trading back and forth.
And BIIB used said $1.5B from that pump and dump of a FDA review BS
How else would BP continue to be BP. Gobbling up baby bio companies are their bread and butter. They don’t invent most of the poisons that get approved.
8 course meal.....
Why else would Missling have mentioned Shake it Up Foundation (Aug2020) in a separate PR? I thought P3 was a forgone conclusion.....
Medical Monitoring, Defined
Medical monitoring is an essential component of the clinical research process. Medical monitors provide medical expertise and oversight for the entire clinical trial, from initial study design through final study close-out. They ensure the clinical integrity of the trial subjects and provide safety accountability across the duration of the study, while acting as expert points of reference for both investigative sites and study team members.
https://www.c3isolutions.com/blog/medical-monitoring-101/
Don’t look here. This REALLY isn’t a giant golden nugget. If it was, do you think it would only cost $5 for a portion? We are BIG PHARMA. We know what to look for. Don’t listen to anyone else. Amaloid IS the way.......just wait and see.
Meanwhile......BP is drooling like a rabid dog hoping they can get their hands on Blarcamesine at a flash sale price.
Luckily for Anavex, the FDA isn’t the end all be all for the co. Getting approved in the EU or down under are options as well.
Just keeps on chugging....
I like this part.
•Differentiated clinical-stage CNS assets targeting significant and growing markets
• Patent protection to 2030-2039, worldwide rights for all product candidates
Pretty sure it’s something he learned over the years. PRs can be a good thing, but for Anavex it has been used against them. “PR machine” from years past come to mind.
Approval in Rett = BP. Watch the dots just magically connect. If it’s good for Rett, and it’s safe and benefits the PDD group, let’s just off-label it for PDD.....Hey, why not the AD groups too.
Insomnia......depression....ahhh.....
It’s time to see what we have in A-371
ALL MY OWN OPINION
Curious if THAT is why BIIB brought aducanumab back from the dead. It failed in March 2019. Hampel got hired by Eisai in May 2019. aducanumab mysteriously returns from the dead October 2019.
So could Eisai be ready to partner now that they’ve been fooled twice? Or will it take 3 times before they are through with BIIB and it’s lies and start looking for “new” potential for CNS diseases.
Dr. Hampel: sir, I’ve been on board with Anavex and we should take a serious look at Anavex.
Pop the champagne
Looks like BIIB will have to defend itself from a class action
https://apple.news/AX5UitrH2S8uKXfhdmoBE0w
“You are absolutely correct, they will keep looking. There really is no choice.”
In my opinion, I believe Biogen already knows what they want. They were trying to play the long game and have Anavex have a slow death. Snuffing out funding and presenting FUD every time Anavex had anything relevant to present.
Really believe if Anavex was for sale, they would have wasted $75 million on a drug from Pfizer? Of course Millions and Billions are way different.
“Biogen said it will also develop PF-05251749 for irregular sleep-wake rhythm disorder in Parkinson’s disease.”
Hmmm..... wasn’t there a line from ctad that discussed sleep. Guess we beat them to the punch again.
Make no mistake, we hit the wine glass on the dinner table and have everyone’s attention.
You DO know what the primary endpoint was, don’t you?
Oh no, the news from last week......
Right?
If BIIB can end a p3, call it a failure, and still manipulate data to show SOME type of positive on 2 trial but not the other.......Then still think it’ll get approved. Imagine a company that HAS successful endpoints, SHOWS that it’s better than soc, and only side effects are headaches? Oh, and by the way I’ll give you 3 years of data after end of trial on top of everything else.
We all know what happened when Netflix pitched itself to blockbuster.....